Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Greenlight sees value in Chemours

by Michael McCoy
August 1, 2016 | A version of this story appeared in Volume 94, Issue 31

The hedge fund Greenlight Capital disclosed in its second-quarter report to investors that it purchased a stake in the embattled chemical maker Chemours. Greenlight says it bought part of the stake in late 2015 when Chemours’s stock fell in reaction to low titanium dioxide prices. It bought the rest last month after the short seller Citron Research suggested Chemours is headed for bankruptcy in the wake of lawsuits related to perfluoro­octanoic acid contamination. Greenlight says it believes Chemours’s debt and legal liabilities are manageable.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.